Loading...
Market
How prevalent will Bkemv be in treating PNH and aHUS by May 2025?
4
Resolution / Starting Odds
Dominant new treatment • 25%
Widely used alongside others • 25%
Limited use • 25%
Rarely used • 25%
Healthcare industry reports and usage statistics
Story
FDA Approves $AMGN's Bkemv, First Biosimilar to $AZN's Soliris
May 28, 2024, 10:11 PM
The U.S. Food and Drug Administration (FDA) has approved Amgen Inc's Bkemv, the first biosimilar to AstraZeneca's Soliris. This biosimilar is designed to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis and patients with atypical hemolytic uremic syndrome (aHUS) to inhibit hemolysis. The approval marks a significant milestone as Bkemv is the first interchangeable biosimilar for these rare diseases. The approval is a notable development for $AMGN and $AZN.
View original story
Similar markets
Amgen's Bkemv dominates • 33%
AstraZeneca retains majority market share • 33%
Other competitors gain significant market share • 34%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Fewer than 10 countries • 33%
10-20 countries • 33%
More than 20 countries • 34%
Widespread adoption • 33%
Moderate adoption • 34%
Limited adoption • 33%
Treatment introduced by end of 2025 • 33%
Treatment delayed beyond 2025 • 33%
No treatment introduced • 34%
Widely adopted in over 50 countries • 25%
Adopted in 20-50 countries • 25%
Adopted in less than 20 countries • 25%
Not adopted widely • 25%
Widely adopted • 25%
Moderately adopted • 25%
Rarely adopted • 25%
Not adopted • 25%
Significant Decrease in Hospitalizations • 33%
Moderate Decrease in Hospitalizations • 33%
No Significant Change in Hospitalizations • 34%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%